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strong glycemic and lipid control along with
significant reduction in body weight; studies from
both diet-induced obese mice and db/db mice
models
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Objectives: AMP activated protein kinase (AMPK) regulates the coordination of anabolic and catabolic processes
and is an attractive therapeutic target for T2DM, obesity and metabolic syndrome. We report the anti-
hyperglycemic and anti-hyperlipidemic effects of CNX-012-570 is an orally bioavailable small molecule (molecular
weight of 530 Daltons) that directly activates AMPK in DIO and db/db animal models of diabetes.
Methods: Activity and efficacy of the compound was tested in cell based as well as cell free systems in vitro. Male
C57BL/6 mice fed with high fat diet (HFD) were assigned to either vehicle or CNX-012-570 (3 mg/kg, orally once a
day) for 8 weeks (n = 8). Genetically diabetic db/db mice on chow diet were dosed with vehicle control or CNX-012-570
(2.5 mg/kg, orally once a day) for 6 weeks (n = 8).
Results: CNX-012-570 is a highly potent and orally bioavailable compound activating AMPK in both cell and cell free
systems. It inhibits lipolysis (33%) and gluconeogenesis (28%) in 3T3L1 cells and rat primary hepatocytes respectively. The
efficacy of the molecule was translated to both DIO and db/db animal models of diabetes. CNX-012-570 has reduced
fasting blood glucose levels by 14%, body weight by 24% and fasting serum triglycerides (TG) by 24%. CNX-012-570
showed a 22% reduction in fed serum cholesterol levels and 19% increase in HDL levels.
In db/db mice model, CNX-012-570 has shown 18% decrease in fed glucose and 32% decrease in fasting glucose with a
2.57% reduction in absolute HbA1c. Decrease in serum insulin and glucose AUC indicates the increased insulin sensitivity.
Body weight was reduced by 13% with increased browning of adipose tissue and decreased inguinal and mesenteric fat
mass. There was significant reduction in liver TG and liver total cholesterol.
Conclusions: CNX-012-570 has the potential to control hyperglycemia and hyperlipidemia. It also reduces body weight
gain with an additional benefit of minimizing cardiovascular risks in diabetics.
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AMP- activated Protein Kinase (AMPK) a serine/threo-
nine protein kinase has been postulated as an important
drug target in metabolic syndrome and diabetes because
of its role in regulation of cellular energy metabolic
homeostasis. It is a heterotrimer comprising of a cata-
lytic α, regulatory β and γ subunits [1]. The predominant
heterotrimer combination varies from tissue to tissue.
The phosphorylation of threonine 172 (Thr 172) at alpha
subunit is necessary for activation of AMPK. The initi-
ation of AMPK activation occurs when AMP binds to the
γ regulatory subunit followed by conformational changes
in α, β and γ [2].
AMPK activation happens in the cell under the low
energy conditions (decrease in ATP and increase in
AMP). Upon phosphorylation, AMPK drives multiple
cellular signaling pathways which can be antagonized by
dephosphorylation with protein phosphatases [3-5]. It is
known by recent findings that AMPK heterotrimer
changes its distribution and localization between cyto-
plasm and nucleus [6-9] with the help of nuclear export
sequence in the catalytic subunit of AMPK [10].
It is well established that AMPK activity is reduced
in the diabetic or metabolic syndrome condition [11].
AMPKα2 deletion has shown to reduce insulin sensi-
tivity, impaired glucose tolerance along with defects in
insulin secretion [12,13]. Impaired AMPK activation is
associated with reduced mitochondrial function and
dysregulated intracellular lipid metabolism [14].
In liver, AMPK activation reduces cholesterol synthesis
by inhibiting HMGCR [15]. In the adipose tissue, AMPK
activation has a direct negative impact on lipolysis
through phosphorylation of HSL at Ser 565 and ATGL
at Ser 406 [16]. In the skeletal muscle, both leptin [17]
and adiponectin [18] activates AMPK whereas exercise
mediated AMPK activation depends on local signaling
pathways. Apart from its role in metabolism, it is known
that AMPK activation is anti-inflammatory and exerts
immunosuppressive effects in different cells [19].
In the past, attempts were made to activate AMPK
either directly or indirectly in order to get the potential
benefit to manage the metabolic syndrome. AICAR (5-
aminoimidazole-4-carboxamide ribonucleoside) which
mimics AMP thereby activates AMPK whereas metfor-
min activates AMPK by increasing the ratio of AMP/
ATP. Many natural compounds like resveratrol and
berberine also activate AMPK by changing the nucleo-
tide ratio [20]. Major concern with these indirect acti-
vators is that one arm of activation is through AMPK
apart from their role in other cellular signaling which is in-
dependent of AMPK activation. Small molecule activators
like ETC-1002 which apart from inhibiting ATP citrate
lyase (ACL-a key enzyme in the cholesterol biosynthetic
pathway), activates AMPK which is independent of LKB1and CAMKKβ [21]. Many attempts were made to activate
AMPK directly using specific small molecule activators.
One of them is A-769662 [22] which is a β1-subunit
specific with no detectable binding or activity towards
β2-subunit.
Our understanding of the AMPK target biology revealed
that AMPK activation has to be in multiple tissues (like
liver, adipose, skeletal muscle, heart, endothelium and
pancreas) in order to get the complete benefit of its activa-
tion on metabolic syndrome that includes CVD risks.
Since each subunit of AMPK exists in different heterotri-
mer, we need to target all the different heterotrimers in
multiple tissues. In this regard, our medicinal chemistry
approach was to target both β1 and β2 subunits to activate
all the AMPK heterotrimers that are present across mul-
tiple tissues. In this study, we report CNX-012-570 (which
has an half-life of 5 h in mice) is a dual β1 and β2 subunit
specific potent and direct AMPK activator for its potential
to control multiple aspects of metabolic syndrome in both
diet-induced obese (DIO) and db/db mice.
Methods
Reagents
3T3L1 (Mouse embryonic fibroblast), C2C12 (Mouse
myoblasts cell line) and HepG2 (human liver hepatocytes)
cell lines are from ATCC. Antibodies against phospho-
AMPKα, AMPKα, phospho-AKT, AKT, phospho-HSL,
phospho-mTOR, phospho-JNK, p-eIF2a and β-Actin
are from Cell Signaling. Anti-HNF4α antibody is from
BioVision. Glucose estimation kit and free glycerol es-
timation kit from Sigma.
Accu-check glucometer from Roche Diagnostics
(Germany) and Ultra-sensitive insulin ELISA kit from
Crystal Chem Inc (USA). Triglyceride and Cholesterol esti-
mation reagents are from Diagnostic Systems (Germany).
FFA estimation kit from Randox (UK) and Glycerol estima-
tion kits from Sigma. Triton-X and Fluromount were pro-
cured from Sigma-Aldrich.
Cell culture
C2C12 cells were seeded in 24-well plates (3 × 104 cells/
well) at 37°C in DMEM containing 25 mM Glucose and
10% FBS. When the cells were confluent, the media was
supplemented with 25 mM glucose and 2% FBS for
myotubes formation. After 4 days of differentiation
and myotubes formation, cells were used for the differ-
ent treatments.
3 T3-L1 cells were cultured in DMEM supplemented
with 10% bovine calf serum (Hyclone, USA) and 25 mM
glucose in 96 or 24-well tissue culture plates. To induce
differentiation, the culture media was supplemented with
100 nM insulin, 1 μM dexamethasone, and 500 μM iso-
butylmethylxanthine. Media was changed every 2 days
with fresh media containing 100 nM insulin until day 5.
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without insulin.
HepG2 cells were maintained in MEM media with
10% FBS. Cells were seeded in appropriate culture plates
two days prior to the treatment.
Tissue distribution and AMPK activation studies
Swiss albino mice (10 wk, 30 ± 3 g) were orally dosed
with CNX-012-570 (10 mg/kg body wt,) once-daily for 3
days (n = 5). After 3 h of final dose, animals were killed
by cervical dislocation. 100 mg of different tissues like
liver, adipose and skeletal muscle were collected and ho-
mogenized for the analysis of AMPK activation and its
downstream target engagement studies using specific
antibodies by Western blotting.
Efficacy studies in disease models
DIO mice study
Sixteen week old male C57BL/6 J mice were fed on either
high fat diet (HFD) (D12492; 60% kcal from fat; Research
Diets, Inc., New Jersey, USA) or chow diet (10% kcal from
fat) for 11 weeks. After acclimatization period, animals
were selected for the study. Animals were housed in poly-
propylene cages, maintained at 23 ± 1°C, 60 ± 10% humid-
ity, exposed to 12 h cycles of light and dark and provided
ad libitum access to either chow or HFD and water
throughout the acclimatization and experimental period.
Animal experiment protocols and experimental proce-
dures were approved by the Connexios Institutional Ani-
mal Ethics Committee which are in accordance with the
ARRIVE guidelines [23].
DIO animals were assigned to specific treatment groups
based on body weight, glucose AUC during OGTT, fasting
blood glucose and fasting serum TG levels. DIO animals
were randomized into control and CNX-012-570 treat-
ment groups (3 mg/kg, orally once a day). Animals (n = 8)
fed on normal chow diet were served as lean control. DIO
animals in the treatment groups (n = 8) and HFD control
group (n = 8) were fed with HFD throughout the experi-
mental period. Animals in the treatment group received
CNX-012-570, orally once a day as solution in 10% di-
methyl acetamide and 8% cremophor as vehicle for 8
weeks. Lean control and HFD control animals were re-
ceived vehicle orally once a day. Body weight (weekly) and
feed consumption (daily) were recorded. Blood was col-
lected from tail vein for glucose and triglyceride estima-
tion. OGTT was performed on the 8th week of treatment
after 6 h fasting with 2 g/kg of oral glucose challenge.
After 8 weeks of treatment blood was collected from
retro-orbital bleeding for glycerol, free fatty acid, choles-
terol, LDL-C estimation. Animals were then euthanized
and necropsied; liver was excised immediately, weighed
and taken for estimation of triglyceride. Different adipose
depots were separated and weighed.db/db mice study
Six week old male db/db mice from Jackson Lab were
acclimatized for one week and randomized to either ve-
hicle control or CNX-012-570 (2.5 mg/kg, orally once a
day) treatment groups (n = 8) based on the body weight,
fed glucose and fasting glucose. Age matched db/+ ani-
mals served as lean control. Treatment group animals
were administered CNX-012-570, orally once a day as
solution in 10% dimethyl acetamide and 8% cremophor
as vehicle for 6 weeks. Lean control and db/db controls
animals received vehicle orally once a day. Body weight,
fed glucose, fasting glucose (tail snip) were monitored
weekly. At the end of the treatment HbA1c (Siemens
DCA Vantage system kit) and insulin levels (Downers
Grove, USA) were measured. Animals were sacrificed
and liver, adipose depots, muscle and serum were
collected.
Fasting and fed glucose
Blood samples were collected by the tail nipping method
after 6 h fasting and glucose levels were measured using
Accu-check glucometer (Roche diagnostics) once a week
during the entire duration of study. Fed state blood sam-
ples were collected as mentioned above and glucose
levels were measured at every 2 h time intervals upto
16 h and then followed by 4 h intervals upto 24 h.
Oral glucose tolerance test
OGTT was determined after oral glucose load at a dose
of 2 g/kg body weight by oral gavage. Blood glucose was
measured by tail clip method at intervals of 0, 15, 30, 60,
90 and 120 min using Accu-check glucometer (Roche
diagnostics).
Fed and fasting insulin
Fed state and 6 h fasted blood samples were collected by
the retro-orbital puncture and insulin levels were esti-
mated using Crystal chem kit (ELISA). Homeostasis
model assessment of insulin resistance (HOMA-IR) was
employed to assess the status of insulin action.
Serum adiponectin
Blood samples collected at end of the study termination
and total high molecular weight adiponectin levels were
measured using adiponectin ELISA kit from ALPCO
diagnostics according to the manufacturer’s instruction.
Western blotting
HepG2 cells, C2C12 myotubes and 3T3L1 adipocytes
were treated with serum free media containing 0.3 μM
of CNX-012-570 and monitored AMPK activation time
course for 24 h (0.25, 2,4,6,8,12,16 and 24 h). At each
time point, cells were harvested and lysed in lysis buffer.
50 μg of the lysate were separated on 12% SDS-PAGE
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with primary antibody against phospho-AMPKα and total
AMPKα. Signals were developed by enhanced chemilu-
minescence (West Pico, Thermo Scientific, USA).
For ex vivo analysis of protein markers, after the CNX-
012-570 treatment period (Swiss albino mice, DIO mice
and db/db mice), mice were killed by cervical disloca-
tion. 100 mg of tissue from different organs were col-
lected (gastronomes muscle, adipose and liver) in lysis
buffer. Lysates were prepared by homogenization and
50 μg of the lysate from each treatment was used for the
Western blot analysis for different protein markers as
mentioned above.
Measurement of thermogenesis
Mice were housed individually and transferred to a cold
environment with an ambient temperature of 4°C. Rectal
temperature was measured for every 15 min for a total
of 75 min and animals were then brought to room
temperature. The temperature was measured further for
20 min at 10 min intervals.
Estimation of total cholesterol, LDL-C, glycerol and FFA in
serum
Blood was collected from retro orbital under isoflurane
anesthesia was allowed to clot for 30 min at room
temperature followed by centrifugation for 10 minutes at
4°C and serum was collected for analysis. Serum total
cholesterol was measured using fully automated clinical
chemistry analyzer EM360, (Transasia Bio-medicals Ltd)
with ERBA Kits. LDL-C and glycerol were estimated by
colorimetric analysis as per manufacturer’s instruction.
Estimation of liver TG and cholesterol
Tissue TG was extracted according to Folch’s method.
Briefly, lipids were extracted with chloroform: methanol
(2:1) mixture, the organic layer was separated and dried
in a speed vac. The residue was re-suspended in isopro-
pyl alcohol and assayed for TG and cholesterol levels by
using TG and cholesterol quantification kit respectively
(Diagnostic systems, Germany).
Quantitative PCR analysis
After the study termination, 100 mg of liver tissue was
collected from each animal across treatment groups in
TRIZOL (Sigma, USA). RNA was isolated and later con-
verted to cDNA as per the standard protocol. Relative
mRNA levels of SREBP1c (fwd: 5′-AGCAGCCCCTA
GAACAAACAC-3′; rev: 5′-CAGCAGTGAGTCTGCC
TTGAT-3′), MCP-1 (fwd: 5′- AGCACCAGCCAACTC
TCACT-3′; rev: 5′-TCATTGGGATCATCTTGCTG-3′)
and APOB100 (fwd: 5′- AAGCACCCCAAGTGTCACA
A-3′; rev: 5′- ATTTGTACTGCAGGGCGTCA-3′) were
analyzed using SYBR green chemistry.Histopathology
Formalin-fixed, paraffin-embedded tissue sections
from liver and inguinal adipose depot were sectioned
at 4 μm and stained with hematoxylin and eosin (H&E)
stain. Histopathological examination was carried out in
a blinded fashion using Carl Zeiss Axio Scope A1
microscope. The images were captured at magnifica-
tion of ×400 using Prog Res C3 camera attached to the
microscope.
Adipose morphometry
Formalin-fixed, paraffin-embedded tissue sections from
inguinal adipose depot were sectioned at 4 μm and
stained with H&E for adipose morphometry. From each
section 10 different randomly selected microscopic fields
at ×400 magnification were used for evaluation. Adipose
morphometry was carried out using ProgRes Pro, v.2.8.8
image analysis suite. The mean area of adipocytes from
all the groups were statistically analyzed using Graphpad
Prism, v.5.0.
Immunofluorescence and image analysis
For UCP1 immunostaining, subcutaneous adipose sec-
tions were de-paraffinized and blocked in 1% BSA in
PBS for 30 min at RT and incubated with anti-UCP1
(Abcam, USA) primary antibody for 90 min at RT,
followed by washing with PBS. Sections were then incu-
bated with secondary antibody (goat anti-rabbit IgG
Alexa Fluor 555, Molecular Probes, Invitrogen) for
30 min at RT and mounted using fluromount. Localization
of UCP1 was assessed and the images were captured
at ×400 magnification. All adipose sections were viewed
at ×400 magnification, and images were captured using
Zeiss microscope connected via camera to a computer
(progres® capture pro 2.1 camera). Adipocytes size meas-
urement was performed using a computer-assisted
image analysis progres® capture pro software. From
each animal 10 images were captured.
Statistical analysis
All the values are expressed as mean ± SEM; Students
unpaired t test was used for comparing cell based assay
results. One way analysis of variance was performed
followed by Dunnets test for establishing level of signifi-
cance between treatment and control animals. p < 0.05
was considered as significant.
Results
CNX-012-570 activates AMPK in multiple tissues in vitro
and in vivo
CNX-012-570 is a highly potent and direct activator of
AMPK with half maximal effective concentration
(EC50) of 93 nM towards α1β1γ1 isoform (predominant
isoform in liver and adipose tissue) and 285 nM
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etal muscle) (Additional file 1A & B) as established
using recombinant AMPK heterotrimer complexes. CNX-
012-570 activates AMPK in time dependent manner in
hepatocytes, muscle cells and in adipocytes as measured
by the extent of AMPK phosphorylation (Figure 1A). The
activation of AMPK happens as early as 15 min and
reaches a maximum at 4-6 h before it comes back to the
normal level. In order to test the impact of AMPK activa-
tion on cellular outcome, we measured hepatic glucose
output in primary rat hepatocytes and isoproterenol medi-
ated lipolysis in 3T3L1 adipocytes. CNX-012-570 inhibits
both hepatic glucose output (12-28%) and adipose lipolysis
(17-33%) (Additional file 2A & B).
To test AMPK activation and its downstream target
engagement in multiple tissues (liver, skeletal muscle
and adipose) in vivo, Swiss albino mice were treated with
CNX-012-570 acutely (3 doses at 10 mg/kg; orally once
a day). CNX-012-570 activates AMPK in all the tested
tissues and shown its downstream target engagement as
measured with HNF4a phosphorylation degradation in
liver, phosphorylation of ACC in skeletal muscle and
HSL in adipose (Figure 1B). We have also tested the
AMPK activation in both DIO mice on HFD and db/db
mice. AMPK activation in all the tissues (liver, skeletal


























Figure 1 CNX-012-570 activates AMPK in multiple tissues in vitro and
as measured by p-AMPK protein levels in HepG2, C2C12 myotubes an
its downstream targets proteins phosphorylation (HNF4α, ACC and HSL) fro
mice after CNX-012-570 treatment (3 doses; 3 mg/kg, orally once a day)
AMPK activation (p-AMPK protein levels) were measured. CNX-012-570 was d
mice respectively. Blots were developed using specific primary antibodies and
mentioned in the Methods.to control animals. Treatment with CNX-012-570 restored
the AMPK activation in both DIO and db/db mice disease
models (Figure 1C).
CNX-012-570 improves insulin sensitivity and glucose
tolerance
We tested impact of AMPK activation by CNX-012-570
on glucose intolerance in HFD mice. The data indicates
an improvement in glucose intolerance as measured by
an oral glucose tolerance test. Upon chronic CNX-012-
570 treatment, we observed ~10% decrease in glucose
excursion as compared to HFD mice (glucose AUC of
29736 ± 775 in CNX-012-570 treated Vs 32718 ± 680 in
HFD control; P < 0.05) (Figure 2A). We observed a sig-
nificant increase in fasting insulin along with HOMA-IR
in HFD animals compared to lean control (1.74 ± 0.23 vs
0.03 ± 0.04 ng/ml; P < 0.001 for insulin and 27.17 ± 3.04
vs 2.99 ± 0.34; P < 0.001 for HOMA-IR respectively).
Treatment with CNX-012-570 reduced both fasting in-
sulin and HOMA-IR by ~21% and 38% respectively as
compared to HFD control (1.38 ± 0.26 vs 1.74 ± 0.23 ng/ml;
P < 0.05 for insulin and 13.17 ± 0.34 vs 27.17 ± 3.04;
P < 0.01 for HOMA-IR) (Figure 2B & C).
In db/db control mice, fed glucose levels were significantly
high (~450 ± 20 vs ~145 ± 6 mg/dl; P < 0.001) as compared
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in vivo: (A) Kinetics of AMPK activation by CNX-012-570 (0.3 μM)
d 3T3L1 adipocytes. (B) AMPK activation (p-AMPK protein levels) and
m liver, skeletal muscle and adipose tissue respectively from SAM
. (C) At the end of the treatment period in both DIO and db/db mice,
osed with 3 mg/kg and 2.5 mg/kg, orally once a day in DIO and db/db







Figure 2 CNX-012-570 improves insulin sensitivity and glucose tolerance in DIO and db/db mice. (A) OGTT in DIO mice on week 8 of
treatment. Open square-Lean control, closed square -HFD control and Triangle-CNX-012-570 (3 mpk, qd). (D) Fed glucose levels in db/db mice
study were monitored weekly. (B & E) Fasting insulin, (C & F) HOMA IR in both DIO and db/db mice were measured at week 8 and 6 respectively.
Clear bar-lean control, black bar-HFD or db/db control, grey bar-CNX-012-570 treatment (3 and 2.5 mg/kg, orally once a day in DIO and db/db
mouse respectively). All the values are expressed as Mean ± SEM. Statistical comparison between control and treatment group was conducted by
One-way ANOVA followed by Dunnett’s test (*P < 0.05, ** P < 0.01 and *** P < 0.001).
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and reached a significant reduction of ~25% after week 3 as
compared to db/db control animals (343 ± 42 vs 450 ±
20 mg/dl; P < 0.05). This reduction was maintained during
the entire treatment period (Figure 2D). db/db control ani-
mals have shown a high levels of insulin (15.6 ± 1.6 vs 0.4 ±
0.0 ng/ml; P < 0.001) and HOMA-IR (417.73 ± 35.43 vs
3.6 ± 0.44; P < 0.001) compared to control animals.
CNX-012-570 treated db/db animals decreased fasting
insulin by ~66% (5.3 ± 1.4 vs 15.6 ± 1.6 ng/ml; P < 0.001)
and HOMA-IR by 68% as compared db/db animals (135.43
± 35.18 vs 417.73 ± 35.43; P < 0.001) (Figure 2E & F).
CNX-012-570 reduces blood glucose, HbA1c, glycerol and
FFA
HFD control animals exhibited a significantly high levels
of fasting glucose as compared to lean control from
week 1 and maintained during the entire study period
(~180 ± 6 vs ~114 ± 5 mg/dl; P < 0.001). Treatment withCNX-012-570 started reducing the fasting glucose from
week 7 and maintained the same on week 8. The reduction
is 15% as compared to HFD control (155 ± 7 vs 180 ±
6 mg/dl; P < 0.05) (Figure 3A). Also we observed a sig-
nificant 15% decrease in serum glycerol (65 ± 3 vs 79 ±
3 μg/ml; P < 0.05) and free fatty acid (1.09 ± 0.07 vs
1.30 ± 0.05 mmol/l; P < 0.05) with CNX-012-570 treat-
ment as compared to HFD control (Figure 3B & C).
In db/db mice, fasting glucose was very high from
week 1 and reachesd a maximum at week 6 compared to
control animals (439 ± 30.9 vs ~130 ± 7 mg/dl; P <
0.001). Treatment with CNX-012-570 reduced fasting
glucose significantly by 32% (439 ± 30.9 vs 306 ±
22.9 mg/dl; P < 0.01) compared to db/db control and the
decrease was observed from week 3 (Figure 3D). At the
end of the study, HbA1c levels were reduced signifi-
cantly by an overall 2.6% with CNX-012-570 treatment
(32% of HFD control animals; i.e. 5.83 ± 0.44 vs 8.34 ±






Figure 3 CNX-012-570 reduces blood glucose, glycerol and FFA: (A & D) Fasting Glucose levels were monitored weekly in both DIO and
db/db mice respectively. At the end of treatment period, Fasting Serum FFA (B) and glycerol levels (C) were measured in DIO mice. (E)
HbA1c levels in db/db mice at week 6. Clear bar-lean control, black bar-HFD or db/db control, grey bar-CNX-012-570 treatment (3 and 2.5 mg/kg,
orally once a day in DIO and db/db mouse respectively). All the values are expressed as Mean ± SEM. Statistical comparison between control
and treatment group was conducted by One-way ANOVA followed by Dunnett’s test (*P < 0.05, ** P < 0.01 and *** P < 0.001).
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cholesterol and has a potential to reduce macro-vesicular
steatosis
Compared to lean control animals, HFD animals have
shown a significant increase in serum triglyceride levels
(120 ± 4 vs 220 ± 14 mg/dl; P < 0.01). This trend was main-
tained during the entire study period. Treatment with
CNX-012-570 reduced serum triglycerides from week 2
and reached a maximum of 24% on week 8 compared
to HFD control (166 ± 7 vs 220 ± 14 mg/dl; P < 0.001)
(Figure 4A). Also we observed a significant increase in
serum cholesterol levels in HFD control animals than
that of lean control (214 ± 9 vs 118 ± 5 mg/dl; P < 0.001).
CNX-012-570 treated animals have shown a 22% signifi-
cant decrease in serum cholesterol than that of HFD con-
trol (116 ± 7 vs 214 ± 9 mg/dl; P < 0.001) (Figure 4B). In
this study we observed a non-significant 8% reduction
LDL levels (data not shown). After the study termination,
we measured liver triglycerides and cholesterol. Triglycer-
ide levels were high in the HFD control than lean control(12.4 ± 1.4 vs 8.6 ± 0.9 mg/g tissue; P < 0.05). CNX-012-
570 reduced liver triglycerides significantly by 27% as
compared to HFD control (9 ± 0.6 vs 12.4 ± 1.4 mg/g tis-
sue; P < 0.01) (Figure 4D). Liver cholesterol levels were re-
duced by 40% in CNX-012-570 treated animals than that
of HFD control (2 ± 0.12 vs 3.7 ± 0.4 mg/g tissue; P < 0.01)
(Figure 4C).
After the study termination, histological evaluation of
liver from all the 3 groups was performed. HFD control
animals have shown a significant increase in macro-
vesicular steatosis with larger lipid droplets as compared
to lean control. In CNX-012-570 treated animals, a sig-
nificant reduction in macro-vesicular steatosis was ob-
served (Figure 4E). mRNA levels of liver steatosis markers
like SREBP1c (stimulate liver lipid synthesis), monocytes
chemoattractant protein-1 (MCP1, a proinflammatory cyto-
kine) and APOB100 (apolipoprotein of chylomicrons and
low-density lipoproteins (LDL)) were reduced in CNX-012-
570 treatment animals as compared to HFD control ani-
mals (Figure 4F).








Figure 4 CNX-012-570 reduces serum triglyceride, total cholesterol and has a potential to reduce macro-vesicular steatosis in DIO
mice. (A) Fasting serum triglycerides were measured once in two weeks. (B) At week 8, serum fed cholesterol was measured. (C & D) After the
study termination, liver cholesterol and triglyceride levels were measured. (E) Histopathological analysis of formalin fixed liver sections after H&E
staining. (F) After the study termination, mRNA levels of liver SREBP1c, MCP1 and APOB100 were measured as mentioned in materials and
methods. Clear bar-lean control, black bar-HFD control, grey bar-CNX-012-570 treatment (3 mg/kg, orally once a day). All the values are expressed
as Mean ± SEM. Statistical comparison between control and treatment group was conducted by One-way ANOVA followed by Dunnett’s test or
students unpaired t-test as appropriate (*P < 0.05, ** P < 0.01 and *** P < 0.001).
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The change in body weight in the lean control during
the study period was not significant except a small in-
crease after week 6 (24.6 g to 26.6 g). HFD animals have
shown a steady increase in body during the study period
and attain a maximum after week 7 (33 g to 37 g). CNX-
012-570 treated animals started showing a significant de-
crease in body weight from week 3 (11%) and reached a
maximum of 24% on week 6 and maintained the same
till week 8 as compared to HFD animals (Figure 5A).
During the course of the study, feed consumption was
recorded weekly and did not observe any change in the
consumption rate across the treatment groups (data not
shown). Also we observed a significant 40-50% decrease
in adipose depot weight in CNX-012-570 treated animals
than that of HFD animals (Figure 5B). Morphometryanalysis of inguinal adipose depot revealed a significant
decrease in adipocytes size in CNX-012-570 treated
animals as compared to the HFD control animals
(Figure 5C).
In db/db animals, the body weight gain was significant
from week 1 to week 6 (33 g to 39 g) whereas control ani-
mals maintained a steady body weight during the study
period (23.6 g on week 1 to 24 g on week 6). Treatment
with CNX-012-570 started decreasing body weight signifi-
cantly on week 2 (10%) and reached a maximum decrease
of 16% on week 5 and maintained till week 6 (Figure 5D)
without change in the feed consumption during the study
period (data not shown). At the end of the study, we mea-
sured the adipose depot weight and found CNX-012-570
treatment decreased 20% of both mesenteric and inguinal





Lean control HFD control CNX-012-570
E
BA
Figure 5 CNX-012-570 reduces body weight: (A & D) Body weight from both the treatment group was measured weekly. Open square-
Lean control, closed square-HFD or db/db control and Triangle-CNX-012-570 treatment. (B & E) At end of the treatment period, different adipose
depot weight was measured from both DIO and db/db mice study respectively. (C) Histology of inguinal adipose tissue sections were analyzed
after H&E staining. Clear bar-lean control, black bar-HFD or db/db control, grey bar-CNX-012-570 treatment (3 and 2.5 mg/kg, orally once a day in
DIO and db/db mouse respectively). All the values are expressed as Mean ± SEM. Statistical comparison between control and treatment group
was conducted by One-way ANOVA followed by Dunnett’s test (*P < 0.05, ** P < 0.01 and *** P < 0.001).
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stress
Insulin sensitivity was assessed by measuring phospho-
AKT in both DIO mice and db/db mice. When compared
to lean control, both HFD control and db/db control ani-
mals showed a decrease in phospho-AKT by 40-50%.
Treatment with CNX-012-570 restored the phospho-AKT
levels to lean control level and the insulin sensitivity (top
panel, Figure 6A&B). Also we observed a reduction in
serum adiponectin levels which was restored to lean con-
trol level by the CNX-012-570 treatment (Figure 6D).
Phospho-JNK in liver in both the disease models, ob-
served a significant 2-3 fold increase in phospho-JNK
levels as compared to respective lean control. Treatment
with CNX-012-570 reduced the phospho-JNK levels
which are comparable to the respective lean control(bottom panel, Figure 6A&B). Also we have observed a
significant ~2 fold increase in both phospho-eIF2α and
phospho-mTOR levels in the HFD control animals. Treat-
ment with CNX-012-570 reduced both phospho-eIF2α
and phospho-mTOR levels significantly (Figure 6C).
CNX-012-570 enhances non-shivering thermogenesis
We observed a similar basal body temperature in all the
animals from 3 groups. After moving the animals to 4°C,
the drop in the temperature was ~5-6% in both HFD
control and CNX-012-570 treated animals after 15th min
as compared to lean control. After 30thmin, there was
further drop in temperature in HFD animals and contin-
ued till 75thmin (the drop was ~14%) before it came
back to normal after 90thmin. On the other hand, CNX-
012-570 treated animals maintained a drop of 5% till
CBA
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Figure 6 CNX-012-570 improves insulin signaling and reduces stress in DIO and db/db mice models: At the end of the treatment
period in both DIO and db/db mice, both liver and skeletal muscle tissues were collected for the analysis of both insulin sensitivity
and stress markers. (A & B) phospho-AKT levels in skeletal muscle (upper panel) and phospho-JNK levels in liver (lower panel) from both DIO
and db/db mice study respectively. (C) phospho-mTOR (upper panel) and phospho-eIF2α (lower panel) levels from skeletal muscle from DIO
mice. L- Lean control, D- DIO or db/db control, T- CNX-012-570 treatment. (D) Serum adiponectin levels from db/db mice study. Clear bar-lean
control, black bar-db/db control, grey bar-CNX-012-570 treatment (2.5 mg/kg, orally once a day). Statistical comparison between control and treatment
group was conducted by One-way ANOVA followed by Dunnett’s test (*P < 0.05, ** P < 0.01 and *** P < 0.001).
Anil et al. Cardiovascular Diabetology 2014, 13:27 Page 10 of 14
http://www.cardiab.com/content/13/1/2760thmin and were equivalent to lean control after 70thmin
(Figure 7A). After observing an adaptive mechanism for
the cold temperature by CNX-012-570 treated animals,
we measured the expression of UCP1 in the inguinal fat.
There was a significant decrease in the UCP1 expression
in HFD control animals whereas CNX-012-570 treated
animals restored the expression. The increase in the
UCP1 expression was corroborated with decrease in adi-
pocytes size in CNX-012-570 treated animals as compared
to HFD control (Figure 7B).
Discussion
In the present study, we have used a direct and selective
AMPK activator CNX-012-570 to evaluate its potential
to modulate the various metabolic abnormalities in both
DIO mice on HFD and db/db mice. These metabolic ab-
normalities were monitored weekly over the period of 6
and 8 weeks in DIO and db/db mice respectively.
AMPK activation has been reported by various mecha-
nisms. AICAR activates AMPK after converting to ZMP
which mimics the effect of AMP [24]. A-769662 and sa-
licylate activate AMPK by binding to glycogen binding
domain on β1-subunit [25,26]. Since CNX-012-570 is
not an AMP mimetic and did not change nucleotide
levels like metformin [27] (Additional file 3A & B), this
activation is a direct interaction of the compound with
the AMPK heterotrimeric complex. Since CNX-012-570is a dual β1 and β2 agonist, we expect the compound ac-
tivates all AMPK heterotrimers across the tissues. This
has been substantiated by our data both in vitro and
ex vivo from multiple cell types (hepatocytes, muscle
cells, adipocytes, endothelial cells and macrophages) and
tissues (liver, skeletal muscle and adipose tissue) respect-
ively. Also our data clearly shows that AMPK activation
triggered the downstream signaling (in terms of its
downstream target engagement: phosphorylation of ACC
and HSL) which is necessary to bring changes in the meta-
bolic state of each tissue.
Impact on hyperglycemia and insulin sensitivity
In both the animal models of disease, it is evident that
AMPK activation in liver and adipose is significantly
compromised. Chronic activation of AMPK (6-8 weeks)
has shown a significant decrease in both fasting plasma
glucose and insulin in both animal models of insulin re-
sistance. Also, decreased gluconeogenic substrates like
FFA and glycerol from adipose (also seen inhibition of
lipolysis in vitro; supplementary data) and alanine (data
not shown) from muscle support the decrease in fasting
glucose levels. One of the known mechanisms of con-
trolling fasting glucose by AMPK is by repressing the
HNF4α mediated transcription of gluconeogenic genes
in liver [15]. Apart from decreasing hepatic gluconeo-
genesis in rat primary hepatocytes (supplementary data),
BA
Lean control HFD control CNX-012-570
UCP1
UCP1
Figure 7 CNX-012-570 enhances non-shivering thermogenesis (DIO): (A) Non-shivering thermogenesis was measured as described in
the Methods. Open square-Lean control, closed square-HFD control and triangle-CNX-012-570 treatment. (B) Immunohistochemistry of UCP1
in subcutaneous adipose tissue sections as mentioned in the Methods.
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levels by CNX-012-570 (data not shown) indicating its
direct role in controlling fasting glucose.
Improved insulin sensitivity (reduced hyperinsuline-
mia) with CNX-012-570 was translated into reduced glu-
cose intolerance and fed glucose levels in both DIO
mice and db/db mice study respectively. We observed
reduction in fed glucose levels from week 2 of the treat-
ment in db/db mice. We observed a good 24 h glucose
control (feed was provided all the time, data not shown)
upon CNX-012-570 treatment in db/db study confers
the overall improvement in glucose tolerance. This kind
of acute control was observed with AICAR. Though the
effect is partly due to AMPK activation, most of the
control was attributed to its ability to inhibit fructose-1,
6-bisphosphatase (a key enzyme in gluconeogenic path-
way) by ZMP [28]. Also we observed a significant increase
in the phospho-AKT levels in both the animal models
upon AMPK activation indicating improved insulin sensi-
tivity/signaling in skeletal muscle and thus support the
mechanistic root for the control of fed glucose. A similar
kind of improved insulin sensitivity was observed when
activation of AMPK/SIRT1 signaling pathway by telmi-
sartan in skeletal muscle [29]. Hyperinsulinemia is
known to increase mTOR/p70 S6K pathway and in-
creased IRS-1/2 serine phosphorylation indicating in-
sulin resistance state of a tissue [30]. Also increase
phopsho-eIF2α levels are associated with increasedglucose intolerance and insulin resistance [31]. Treat-
ment with CNX-012-570 reduced hyper-phosphorylated
mTOR and phopsho-eIF2α indicating an improvement in
insulin sensitivity and normalization of protein synthesis.
We observed a significant reduction in liver phospho-JNK
indicating improved liver insulin sensitivity also. Serum
adiponectin levels were reduced in db/db mice and
observed a significant improvement upon CNX-012-570
treatment. This was reflected in significant reduction in
HOMA-IR and HbA1c levels. These data from different
tissues indicates that CNX-012-570 improves whole body
insulin sensitivity through multiple mechanisms.
Impact on dyslipidemia and nonalcoholic fatty liver
disease (NAFLD)
In DIO mice, treatment with CNX-012-570 has reduced
circulating TG levels significantly along with a modest
reduction serum FFA. The reduction in TG was appreci-
ated at week 2 of treatment. Also this could be due to
decrease in adipose lipolysis, decreased storage or in-
creased fat oxidation in liver. Our data clearly demon-
strates that CNX-012-570 inhibits adipose lipolysis and
ex vivo studies from liver clearly shows a reduction in
expression of SREBP1c mRNA levels and other lipogenic
markers indicating decreased lipogenesis. The role of
AMPK in regulating lipogenesis by reducing both activ-
ity and expression of SREBP1c is well established
[32,33]. Treatment with CNX-012-570 decreased serum
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the DIO mice on HFD. The decrease in liver cholesterol
is a direct consequence of AMPK activation by CNX-
012-570. It is well known that AMPK activation leads
to decrease in cholesterol biosynthesis. It happens at
two levels, one at the transcriptional level where
AMPK reduces SREBP1c transcription [32] which is
known to transcribe HMG-CoA reductase (HMGCR) a
rate-limiting enzyme in cholesterol synthesis. The other
regulation is at the inactivation of HMGCR activity by
phosphorylation [33,34]. Our data clearly demonstrates
that CNX-012-570 decreases SREBP1c and APOB100
mRNA levels in liver and increases phospho-HMGCR
levels in HepG2 cells (supplementary data). Even though
further studies in appropriate animal models are neces-
sary, these data indicates that CNX-012-570 potential to
reduce hypercholesterolemia.
NAFLD starts with fatty liver (hepatic steatosis), can
progress to nonalcoholic steatohepatitis (NASH) and end
up with liver fibrosis and cirrhosis. In metabolic syndrome
that includes obesity, type 2 diabetes and dyslipidemia (el-
evated TG levels) are associated with NAFLD/NASH [35].
It is proven in humans that treatment of NAFLD with a
good insulin sensitizer like metformin has a favorable
benefit towards hepatic steatosis. It is speculated that the
effect seen may be independent of its glycemic controlling
mechanisms [36]. Even though metformin effect on gly-
cemic control is known to be by AMPK dependent/inde-
pendent activation, the mechanism of metformin action in
NAFLD is not established. In HFD control mice, we ob-
served a significant increase in both liver TG and serum
TG. The increase in liver TG is associated with increase in
macro vesicular steatosis in the HFD control animals.
Treatment with CNX-012-570 decreased both liver TG
and macro vesicular steatosis significantly. Increased ex-
pression of both lipogenic marker SREBP1c and proin-
flammatory cytokine MCP-1 are known to induce liver
steatosis [37,38]. AMPK activation with CNX-012-570 re-
duced both SREBP1c and MCP-1 mRNA levels signifi-
cantly. These results indicate a direct role of AMPK in
controlling the hepatic steatosis. Some more studies are
needed to strengthen AMPK role in NASH and liver
fibrosis.
Impact on body weight and energy expenditure
In our both DIO and db/db mice study, the weight of
disease control animals increased progressively during
the study period. Treatment with CNX-012-570 reduced
the body weight gain in both the models significantly. In
fact we observed a 10% decrease in body weight in DIO
mice study. The body weight reduction was observed at
week 2 of treatment. This kind reduction has observed
only when there is an enhanced fat oxidation by physical
activity, marked improvement in insulin sensitivity, normaladiponectin levels and decreased depots of adipose tissue
[39,40]. When we measured the weight of each depot,
there was a significant decrease in each depot weight in
CNX-012-570 treated animals except in epididymal depot
of db/db treated animal. Apart from decreased adipose de-
pots, there was a significant reduction in inguinal adipo-
cytes size. AMPK activation by AICAR is known to
increase uncoupling protein-1 (UCP1) expression in white
adipose tissue and increase thermogenesis, which can po-
tentially increase energy expenditure and fat oxidation
[41]. In DIO mice study, apart from slow recovery the drop
in the rectal temperature was significant in the HFD con-
trol animals compared to the lean control. CNX-012-570
treated animals recovered very quickly like the lean control
animals and the drop was not significant as compared to
HFD animals indicating enhanced energy expenditure and
fat oxidation. Increased UCP1 protein staining substanti-
ated our claim further that CNX-012-570 treatment has a
potential to increase the browning phenotype of white adi-
pose tissue.
Future direction
Recent studies have shown that glycocalyx layer has
been damaged or degraded in chronic hyperglycemia
[42]. Metformin treatment has shown a clear improve-
ment in the glycocalyx barrier [43]. Since most of the
metformin effects are through AMPK activation, impact
of CNX-012-570 on improvement in glycocalyx barrier
will be assessed in the later studies.
In heart, AMPK activation is known to protect cardio-
myocytes apoptosis by regulating cardiac autophagy [44].
AMPK activation also protects heart during myocardial
ischemia-reperfusion injury by activating the pro-survival
kinases like AKT, ERK1/2 and GSK3ß [45]. Our prelimin-
ary results have shown that CNX-012-570 protects heart
from myocardial ischemia-reperfusion injury (manuscript
in preparation).
Conclusions
In summary, CNX-012-570 is a direct and selective, or-
ally bioavailable dual β1 & β2 AMPK activator. Pharma-
cological activation of AMPK with CNX-012-570 can
give strong glycemic control and improve insulin sensi-
tivity. It can reduce serum and tissue lipid levels signifi-
cantly with a potential control the hepatic steatosis.
Some more independent studies need to be performed
to evaluate CNX-012-570 potential as a stand-alone
anti-dyslipidemic agent. CNX-012-570 has a potential to
reduce body weight.
CNX-012-570 is an early lead in our discovery pro-
gram. CNX-012-570 is a safe, metabolically stable with
no risk of drug-drug interaction. Long-term safety and
toxicity studies in multiple species will be necessary to
progress for studies in humans.
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Additional file 1: CNX-012-570 activates both β1 and β2 sub-unit
containing AMPK heterotrimer.
Additional file 2: CNX-012-570 mediated activation of AMPK
inhibits both hepatic glucose output and adipose lipolysis.
Additional file 3: CNX-012-570 is a direct activator of AMPK and
not an AMP mimetic.
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